Compare JPMorgan Equity Premium Income ETF (JEPI) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs ResMed Inc. — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.62, while ResMed Inc. trades at $196 (market cap $28.81B). The key difference: ResMed Inc. pays a 1.21% dividend while JPMorgan Equity Premium Income ETF pays none, and JPMorgan Equity Premium Income ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| JEPI | RMD | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $293.73 |
52-Week Low | $55.29 | $182.82 |
Market Cap | — | $28.81B |
Enterprise Value | — | $27.99B |
Dividend Yield | — | 1.21% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
